Navigation Links
Inovio Pharmaceuticals to Ring Opening Bell Nov 25th on the Nasdaq Stock Market
Date:11/24/2014

PLYMOUTH MEETING, Pa., Nov. 24, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today that Dr. J. Joseph Kim, President and CEO of Inovio Pharmaceuticals, will be joined by members of the company's board and management team to ring the Nasdaq Opening Bell tomorrow, Tuesday November 25, 2014, at 9:30 a.m. ET, in celebration of Inovio's September 15th listing on the Nasdaq Global Select Market. 

Commenting on the bell ringing ceremony, Dr. Kim said, "We are honored to ring the Nasdaq Opening Bell on behalf of all of our dedicated employees, investors and all stakeholders. Our listing on the Nasdaq Global Select Market marks another milestone for Inovio as we advance our company toward a phase III clinical trial and advance our other DNA immunotherapies into the clinic."

A webcast of Inovio's ceremony at the Nasdaq Opening Bell will be available at:
https://new.livestream.com/nasdaq/live or http://www.nasdaq.com/about/marketsitetowervideo.asx

About Inovio Pharmaceuticals, Inc.

Inovio is revolutionizing the fight against cancer and infectious diseases. Our immunotherapies uniquely activate best-in-class immune responses to prevent and treat disease, and have shown clinically significant efficacy with a favorable safety profile. With an expanding portfolio of cancer immunotherapies and clinical studies, the company is advancing a growing product pipeline. Partners and collaborators include Roche, MedImmune, the University of Pennsylvania, DARPA, Drexel University, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, US Dept. of Homeland Security, and University of Manitoba. For more information, visit www.inovio.com.

This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines, our expectations regarding our research and development programs and our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in this release may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve the results desired, including safety and efficacy for VGX-3100, that pre-clinical studies and clinical trials may not commence or be completed in the time periods anticipated, that results from one study may not necessarily be reflected or supported by the results of other similar studies and that results from an animal study may not be indicative of results achievable in human studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, our ability to support our broad pipeline of SynCon® active immune therapy and vaccine products, our ability to advance our portfolio of immune-oncology products independently, including INO-5150, and to commence a phase I clinical trial for INO-5150 in the first half of 2015, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that the company and its collaborators hope to develop, our ability to enter into partnerships in conjunction with our research and development programs, evaluation of potential opportunities, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company's technology by potential corporate or other partners or collaborators, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2013, our Form 10-Q for the quarter ended September 30, 2014, and other regulatory filings from time to time. There can be no assurance that any product in Inovio's pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate.

CONTACTS:

Investors: Bernie Hertel, Inovio Pharmaceuticals, 858-410-3101, bhertel@inovio.com
Media: Jeff Richardson, Inovio Pharmaceuticals, 267-440-4211, jrichardson@inovio.com

Logo - http://photos.prnewswire.com/prnh/20131118/LA18202LOGO


'/>"/>
SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
2. Inovio Pharmaceuticals Reports 2012 First Quarter Financial Results
3. Inovio Pharmaceuticals to Present at SPI 2012
4. Inovio Pharmaceuticals Universal Avian Flu Vaccine Generates Protective Antibody Responses Against Six H5N1 Viruses in Phase I Trial
5. Inovio Pharmaceuticals to Present at JMP Investor Conference
6. Inovio Initiates H1N1 Universal Influenza Vaccine Clinical Trial Targeting Over-65 Population, Which Represents 90% of Flu Deaths
7. Inovio Pharmaceuticals Inc. to Webcast, Live, at RetailInvestorConferences.com on August 2nd
8. Inovio Pharmaceuticals Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
9. Inovio Pharmaceuticals Reports 2012 Second Quarter Financial Results
10. Inovio Pharmaceuticals Takes Major Stride Toward Universal Influenza Vaccine
11. Inovio Pharmaceuticals Reports 2012 Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2018)... ... December 14, 2018 , ... When it comes to ... often the case for alleviating the chronic, gnawing pain caused by degenerating or damaged ... , As a minimally-invasive, conservative option for bringing his patients relief, Dr. ...
(Date:12/14/2018)... CHICAGO (PRWEB) , ... December 14, 2018 , ... ... gratitude to our corporate partners sponsoring the Becker's Hospital Review 10th Annual Meeting ... than 300 hospital and health system executive speakers comprise a full agenda of ...
(Date:12/13/2018)... ... 2018 , ... Dr. Cory M. Lessner, Laser vision correction ... The Haute Beauty Network, well known for their exclusivity, and luxurious lifestyle publication ... newest addition to the Haute Living partnership. , Haute Beauty offers a ...
Breaking Medicine Technology:
(Date:12/14/2018)... ... 14, 2018 , ... Becker's Hospital Review is pleased to welcome Super Bowl ... artist and Entrepreneur Bobbi Brown; and Founder of KevinMD.com Kevin Pho, MD, as celebrity ... 2 to 4 at the Swissotel in Chicago. The event will include eight keynote ...
(Date:12/13/2018)... MELBOURNE, Fla. (PRWEB) , ... December 13, 2018 , ... ... inducted into the RealSelf Hall of Fame, an honor recognizing the highest-rated and most ... treatments and connect with medical aesthetic providers. Dr. Clevens has been named a “Distinguished ...
(Date:12/13/2018)... ... , ... Shady Grove Fertility (SGF) welcomes reproductive ... patients at SGF’s Woodbridge, VA location. Dr. Swelstad will provide patients ... for female and male infertility, as well as elective fertility preservation, oncofertility care ...
(Date:12/13/2018)... ... December 13, 2018 , ... Researchers at the Icahn School of Medicine ... induces the highest rate of proliferation ever observed in adult human beta cells—the cells ... diabetes treatment that restores the body’s ability to produce insulin. , The finding involved ...
(Date:12/13/2018)... ... 2018 , ... LifeStation today announced the availability of Find My Loved One, a premium feature ... caregivers the ability to locate a loved one at any time. With the ability ... mind for children, relatives, and caregivers. , Here’s how it works: , 1. ...
Breaking Medicine News(10 mins):